Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells

British Journal of Ophthalmology

Volumn 95, Issue 8, 2011, Pages 1151-1156

  Deissler, Heidrun L ^a   Deissler, Helmut ^a   Lang, Gabriele E ^a  

^a UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 1; RANIBIZUMAB; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; RECOMBINANT GROWTH FACTOR; RECOMBINANT SOMATOMEDIN C; RECOMBINANT VASCULOTROPIN 165; TIVOZANIB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CELL IMMORTALIZATION; CELL MEMBRANE PERMEABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; COW; DIABETIC MACULAR EDEMA; DRUG MECHANISM; ELECTRIC RESISTANCE; IN VITRO STUDY; MICROVASCULAR ENDOTHELIAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TARGETING; RETINA CELL; TIGHT JUNCTION; TRANSENDOTHELIAL ELECTRIC RESISTANCE; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CAPILLARY PERMEABILITY; CATTLE; CELL LINE, TRANSFORMED; DRUG INTERACTIONS; ELECTRIC IMPEDANCE; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; INSULIN-LIKE GROWTH FACTOR I; MEMBRANE PROTEINS; PHENYLUREA COMPOUNDS; QUINOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETINAL VESSELS; TIGHT JUNCTIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960620834     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.192229     Document Type: Article

References (26)

1. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7. (Pubitemid 24356306)
2. Boulton M, Gregor Z, McLeod D, et al. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol 1997;81:228-33. (Pubitemid 27120890)
3. Meyer-Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous levels of the insulin-like growth factors I and II and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J Clin Invest 1993;92:2620-5. (Pubitemid 24006525)
4. Malecaze F, Clamens S, Simorre-Pinatel V, et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994;112:1476-82. (Pubitemid 24350514)
5. Watanabe D, Suzuma K, Suzuma I, et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2005;139:476-81. (Pubitemid 40379074)
6. Javerzat S, Auguste P, Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol Med 2002;8:483-9.
7. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611. (Pubitemid 39099316)
8. Yan Q, Ki Y, Hendrickson A, et al. Regulation of retinal capillary cells by basic fibroblast growth factor, vascular endothelial growth factor, and hypoxia. In Vitro Cell Dev Biol Anim 2001;37:45-9. (Pubitemid 32245953)
9. Castellon R, Hamdi HK, Sacerio I, et al. Effects of angiogenic growth factor combinations on retinal endothelial cells. Exp Eye Res 2002;74:523-35. (Pubitemid 34757030)
10. Deissler H, Deissler H, Lang GK, et al. Generation and characterization of iBREC: novel hTERT-immortalized bovine retinal endothelial cells. Int J Mol Med 2005;16:65-70.
11. Hata Y, Rook SL, Aiello LP. Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44/p42 mitogen-activated protein kinase-dependent pathway. Diabetes 1999;48:1145-55. (Pubitemid 29226364)
12. Haurigot V, Villacampa P, Ribera A, et al. Increased intraocular insulin-like growth factor-I triggers blood-retinal barrier breakdown. J Biol Chem 2009;284:22961-9.
13. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001;42:2408-13. (Pubitemid 32848873)
14. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006;142:961-9.
15. Deissler H, Deissler H, Lang S, et al. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis®) in microvascular retinal endothelial cells. Br J Ophthalmol 2008;92:839-43. (Pubitemid 351839580)
16. 165 on tight junction protein claudin-1 and permeability in microvascular retinal endothelial cells. Invest Ophthalmol Vis Sci 2010;51:535-42.
17. Bazzoni G. Endothelial tight junctions: permeable barriers of the vessel wall. Thromb Haemost 2006;95:36-42.
18. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-70. (Pubitemid 44547437)
19. Nakamura K, Taguchi E, Miura T, et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 2006;66:9134-42. (Pubitemid 44521133)
20. Antonetti DA, Wolpert EB, DeMaio L, et al. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem 2002;80:667-77. (Pubitemid 34809975)
21. Tretiach M, van Driel D, Gillies MC. Transendothelial electrical resistance of bovine retinal capillary endothelial cells is influenced by cell growth patterns: an ultrastructural study. Clin Exp Ophthalmol 2003;31:348-53. (Pubitemid 37127457)
22. Simorre-Pinatel V, Guerrin M, Chollet P, et al. Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway. Invest Ophthalmol Vis Sci 1994;35:3393-400. (Pubitemid 24337944)
23. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: chrystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999;293:865-81. (Pubitemid 29527672)
24. Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the Ranibizumab for Edema of the macula in Diabetes (READ-2) study. Ophthalmology 2009;116:2175-81.
25. Elman MJ, Aiello LP, Beck RW, et al; Diabetic Retinopathy Clinical Research Network, Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77.
26. Wang D, Donner DB, Warren RS. Homeostatic modulation of cell surface KDR and Flt1 expression and expression of the vascular endothelial cell growth factor (VEGF) receptor mRNAs by VEGF. J Biol Chem 2000;275:15905-11. (Pubitemid 30366892)